NMDA/calcium channel antagonists (Allelix)

N/A

Report date: 2025/03/20 20:00:06
NME

Base Information

Drug NameNMDA/calcium channel antagonists (Allelix)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionVoltage-gated calcium channel blockersGlutamate [NMDA] receptor antagonists
TargetsVoltage-gated calcium channelGlutamate [NMDA] receptor
Therapy Area/IndicationsNerve DegenerationCraniocerebral TraumaEpilepsy +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanada
CombinationsNo
Global Highest StatusDiscontinued (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesNps Allelix Corp
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNps Allelix Corp
Active IndicationsN/A
Inactive IndicationsNerve DegenerationCraniocerebral TraumaEpilepsy +[6] 

Other Information

ATC CodeN/A
Related LinksN/A